Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of RISPERDAL and RISPERDALORO in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
Like all other antipsychotics (including typical an tipsychotics), RISPERDAL and RISPERDALORO provide a moderate improvement in actual benefit (IAB III) in the treatment of schizophrenia. |
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
SS521rDAzg09GT5y
